Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 10/20 | 0.39 |
| ▸ | LAP3 | P28838 | 5/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242322 | 0.85 | F2 (0.39) | ITGB3ITGB1ITGAVITGA2BITGB5 | |
| SCHEMBL3775825 | 0.82 | KDM4E (0.33) | PLAU | |
| SCHEMBL2358700 | 0.81 | PLAU (0.46) | ITGB3ITGB1ITGAVITGA2BITGB5 | |
| SCHEMBL2242323 | 0.81 | F2 (0.45) | PLAU | |
| SCHEMBL3771902 | 0.79 | PPARA (0.38) | — | |
| SCHEMBL3777967 | 0.78 | SCN2A (0.32) | — | |
| SCHEMBL17894521 | 0.78 | MIF (0.36) | — | |
| SCHEMBL2242826 | 0.77 | PLAU (0.58) | PLAU | |
| SCHEMBL7964967 | 0.77 | — | — | |
| SCHEMBL13738443 | 0.77 | PLAU (0.49) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940856-B1 | NOVEL UROKINASE INHIBITORS | UNIV ANTWERPEN (BE) | 2014-10-08 | — | — | EP | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312191-A1 | Novel Urokinase Inhibitors | PLAU, PLAUR, SERPINE1 | ANPEP 479/4885LAP3 412/4885ERAP2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.